Acute Treatment of Severe Hypertension in Preeclampsia

First-Line Agents for Acute Severe Hypertension

The European Society of Cardiology recommends intravenous labetalol as a first-line medication for acute treatment of severe preeclampsia, due to its safety and effectiveness in controlling blood pressure in severe hypertension 1
The American College of Obstetricians and Gynecologists suggests oral immediate-release nifedipine as an equally appropriate first-line therapy, particularly when IV access is not immediately available, with recent evidence indicating it may be superior to hydralazine in achieving blood pressure control 1
Intravenous hydralazine is associated with more adverse effects, including maternal hypotension, increased cesarean section rates, placental abruption, maternal oliguria, and fetal tachycardia, compared to other agents, according to the European Heart Journal 1

Methyldopa is not recommended for acute hypertensive emergencies due to its slow onset of action, as stated by the European Society of Cardiology 1
Clonidine is not recommended in current guidelines for acute management of severe hypertension in pregnancy, according to the European Heart Journal 1
Sodium nitroprusside should only be used as a last resort in extreme emergencies, due to the risk of fetal cyanide poisoning and increased maternal intracranial pressure, as recommended by the European Society of Cardiology and supported by evidence from 2011 1, 2

The European Society of Cardiology recommends administering IV labetalol starting at 10-20 mg, with repeat doses of 20-80 mg every 20 minutes up to a maximum of 300 mg, if IV access is available 1
The American College of Obstetricians and Gynecologists suggests giving immediate-release oral nifedipine 10-20 mg, repeating in 20-30 minutes if needed, if IV access is not available or preferred 1
The target blood pressure should be reduced by 15-25%, aiming for SBP 140-150 mmHg and DBP 90-100 mmHg, to avoid excessive reduction and prevent uteroplacental hypoperfusion, as recommended by the European Society of Cardiology 1

The European Society of Cardiology warns against using short-acting nifedipine with concurrent magnesium sulfate, due to the risk of uncontrolled hypotension and potential synergistic effects 1
The American College of Obstetricians and Gynecologists recommends monitoring for labetalol-related complications, including maternal bradycardia and potential neonatal bradycardia 1
If hydralazine is used, the European Society of Cardiology advises closely monitoring maternal BP and fetal wellbeing, due to the higher risk of adverse effects that may mimic worsening preeclampsia 1

The American College of Cardiology recommends oral nifedipine, intravenous labetalol, and oral methyldopa as first-line agents for managing blood pressure in pre-eclampsia, with the choice depending on the severity of hypertension and available resources 3, 4
For severe hypertension, the European Heart Journal suggests first-line options including oral nifedipine, intravenous labetalol, and intravenous hydralazine 3, 5
The European Heart Journal recommends methyldopa, labetalol, nifedipine, and oxprenolol as first-line oral agents for non-severe hypertension 3, 4, 6

The American College of Cardiology recommends reducing blood pressure within 30-60 minutes, with a target reduction of 15-25% of mean blood pressure, and a target range of systolic blood pressure 140-150 mmHg and diastolic blood pressure 90-100 mmHg for severe hypertension 3, 7
For non-severe hypertension, the American College of Cardiology recommends a target diastolic blood pressure of 85 mmHg and a target systolic blood pressure of 110-140 mmHg 3, 4

The American College of Cardiology advises avoiding ACE inhibitors, angiotensin receptor blockers, and direct renin inhibitors in pregnancy due to potential harm 8
The European Heart Journal recommends using diuretics with caution, as they may reduce plasma volume, and contraindicates their use in pre-eclampsia with fetal growth restriction 6
The American College of Cardiology recommends monitoring maternal blood pressure, proteinuria, and clinical assessment, including clonus, as well as performing blood tests at least twice weekly for hemoglobin, platelet count, liver enzymes, creatinine, and uric acid 4

The American College of Cardiology recommends delivery at 37 weeks' gestation, or earlier if there are repeated episodes of severe hypertension despite treatment, progressive thrombocytopenia, abnormal liver or renal function tests, pulmonary edema, abnormal neurological features, or non-reassuring fetal status 3, 4